Replies to post #165519 on Amarin Corp Plc (AMRN)

[north40000]

NEJM, 12/06/2018, Toward Precision Policy—The Case of Cardiovascular Care, p. 2190.

Not particularly relevant, IMO. Does discuss a transition in hospital care: delivery of high value, better quality care rather than volume based care, resulting in lower costs. Skim revealed no specific reference to Amarin or Vascepa.; the thought of what Vascepa may accomplish is likely in forefront of Dr. Bhatt’s mind, IMO. Evolution to evidence-based health policy very similar to what I have heard from FDA’s Dr. Gottlieb